254 related articles for article (PubMed ID: 28256401)
1. Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study.
Viaud J; Brac C; Artru P; Le Pabic E; Leconte B; Bodère A; Pracht M; Le Sourd S; Edeline J; Lièvre A
Dig Liver Dis; 2017 Jun; 49(6):692-696. PubMed ID: 28256401
[TBL] [Abstract][Full Text] [Related]
2. Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Vogl UM; Andalibi H; Klaus A; Vormittag L; Schima W; Heinrich B; Kafka A; Winkler T; Öhler L
BMC Cancer; 2019 Jan; 19(1):28. PubMed ID: 30621630
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Riedl JM; Posch F; Horvath L; Gantschnigg A; Renneberg F; Schwarzenbacher E; Moik F; Barth DA; Rossmann CH; Stotz M; Schaberl-Moser R; Pichler M; Stöger H; Greil R; Djanani A; Schlick K; Gerger A
Eur J Cancer; 2021 Jul; 151():3-13. PubMed ID: 33951545
[TBL] [Abstract][Full Text] [Related]
4. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
5. Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer.
Tsang ES; Spratlin J; Cheung WY; Kim CA; Kong S; Xu Y; Gill S
Am J Clin Oncol; 2019 Dec; 42(12):903-908. PubMed ID: 31693510
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.
Gilabert M; Chanez B; Rho YS; Giovanini M; Turrini O; Batist G; Kavan P; Raoul JL
Medicine (Baltimore); 2017 Apr; 96(16):e6544. PubMed ID: 28422841
[TBL] [Abstract][Full Text] [Related]
7. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
[TBL] [Abstract][Full Text] [Related]
8. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study.
Kim JH; Lee SC; Oh SY; Song SY; Lee N; Nam EM; Lee S; Hwang IG; Lee HR; Lee KT; Bae SB; Kim HJ; Jang JS; Lim DH; Lee HW; Kang SY; Kang JH
Cancer Commun (Lond); 2018 Jun; 38(1):32. PubMed ID: 29866170
[TBL] [Abstract][Full Text] [Related]
9. Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
Girardi DM; Faria LDBB; Teixeira MC; Costa FP; Hoff PMG; Fernandes GS
J Gastrointest Cancer; 2019 Dec; 50(4):860-866. PubMed ID: 30175393
[TBL] [Abstract][Full Text] [Related]
10. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641
[TBL] [Abstract][Full Text] [Related]
11. Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
Umemura A; Nitta H; Sasaki A; Takahara T; Hasegawa Y; Wakabayashi G
Hepatogastroenterology; 2014 May; 61(131):814-20. PubMed ID: 26176079
[TBL] [Abstract][Full Text] [Related]
12. Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
Lorgis V; Chauffert B; Gentil J; Ghiringhelli F
Anticancer Res; 2012 Sep; 32(9):4125-30. PubMed ID: 22993372
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Orlandi A; Calegari MA; Martini M; Cocomazzi A; Bagalà C; Indellicati G; Zurlo V; Basso M; Cassano A; Larocca LM; Barone C
Clin Transl Oncol; 2016 Oct; 18(10):988-95. PubMed ID: 26742940
[TBL] [Abstract][Full Text] [Related]
14. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Klein-Brill A; Amar-Farkash S; Lawrence G; Collisson EA; Aran D
JAMA Netw Open; 2022 Jun; 5(6):e2216199. PubMed ID: 35675073
[TBL] [Abstract][Full Text] [Related]
15. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
[TBL] [Abstract][Full Text] [Related]
16. Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
Queck A; Elango S; Koch C; Walter D; Schmidt J; Trebicka J; Trojan J; Pession U; Finkelmeier F; Waidmann O
Oncol Res Treat; 2022; 45(3):79-87. PubMed ID: 34875671
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience.
Zhang H; Kellett C; Lambert P; Kim CA
Clin Colorectal Cancer; 2018 Sep; 17(3):e451-e456. PubMed ID: 29631907
[TBL] [Abstract][Full Text] [Related]
18. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Santucci J; Tacey M; Thomson B; Michael M; Wong R; Shapiro J; Jennens R; Clarke K; Pattison S; Burge M; Zielinski R; Nikfarjam M; Ananda S; Lipton L; Gibbs P; Lee B
Eur J Cancer; 2022 Oct; 174():102-112. PubMed ID: 35988408
[TBL] [Abstract][Full Text] [Related]
19. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
[TBL] [Abstract][Full Text] [Related]
20. An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.
Péron J; Roy P; Conroy T; Desseigne F; Ychou M; Gourgou-Bourgade S; Stanbury T; Roche L; Ozenne B; Buyse M
Oncotarget; 2016 Dec; 7(50):82953-82960. PubMed ID: 27765912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
